Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KRAS | P01116 | 15/20 | 0.78 |
| ▸ | PAK1 | Q13153 | 2/20 | 0.35 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.35 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.35 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21733404 | 1.00 | KRAS (0.78) | KRASPAK1RPS6KB1TRPV1PDGFRB | |
| SCHEMBL30178006 | 1.00 | KRAS (0.78) | KRASPAK1RPS6KB1TRPV1PDGFRB | |
| SCHEMBL21734025 | 1.00 | KRAS (0.78) | KRASPAK1RPS6KB1TRPV1PDGFRB | |
| SCHEMBL30177726 | 1.00 | KRAS (0.78) | KRASPAK1RPS6KB1TRPV1PDGFRB | |
| SCHEMBL30178135 | 1.00 | KRAS (0.78) | KRASPAK1RPS6KB1TRPV1PDGFRB | |
| SCHEMBL24854607 | 1.00 | KRAS (0.78) | KRASPAK1RPS6KB1TRPV1PDGFRB | |
| SCHEMBL21733402 | 1.00 | KRAS (0.78) | KRASPAK1RPS6KB1TRPV1PDGFRB | |
| SCHEMBL21243886 | 0.88 | KRAS (1.00) | KRAS | |
| SCHEMBL21733791 | 0.88 | KRAS (1.00) | KRAS | |
| SCHEMBL21733645 | 0.88 | KRAS (1.00) | KRAS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11760744-B2 | Fused ring compounds | GENENTECH, INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-11760744-B2 | Fused ring compounds | GENENTECH, INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-20230002345-A1 | FUSED RING COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2023-01-05 | — | — | US | disclosed |
| WO-2020035031-A1 | FUSED RING COMPOUNDS | GENENTECH, INC. (US) | 2020-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11760744-B2 | Fused ring compounds | KRAS, NRAS, HRAS | KRAS 1/4885PAK1 229/4885RPS6KB1 27/4885 |
| US-20230002345-A1 | FUSED RING COMPOUNDS | KRAS, NRAS, HRAS | KRAS 1/4885PAK1 229/4885RPS6KB1 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.